Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Nerdwallet Inc (NRDS) Price & Performance

Cassava Sciences IncTrade
Nerdwallet IncTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Nerdwallet Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Nerdwallet Inc trades at $9.74 (market cap $625.17M). The key difference: Nerdwallet Inc is far larger — about 15.9× Cassava Sciences Inc's market cap, and Nerdwallet Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Nerdwallet Inc for 45 Days on average.

FLNANRDS
Market Cap
$39.40M$625.17M
Volume
759,0181,321,316
Sector
HealthMedia
52-Week High
$4.64$15.93
52-Week Low
$0.68$7.58
Typical Hold Time
37 Days45 Days
Enterprise Value
-$43.28M$539.47M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.8136, down 0.26% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent positive news includes FDA lifting a clinical hold on its epilepsy drug, enabling Phase 2a studies.

The outlook remains high-risk due to persistent negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include clinical trial execution and funding needs, while the FDA decision provides a potential catalyst for long-term investors focused on biotech turnaround stories.

Nerdwallet Inc

NerdWallet (NRDS) trades at $9.74, up 7.21% today, showing strong momentum despite a recent Q2 2026 earnings miss. The stock exhibits bullish technical signals with positive moving averages and strong institutional support. Fundamentally, the company demonstrates robust revenue growth from $539M in 2022 to $837M in 2025, with improving profitability margins. Recent news highlights the company's Financial Resilience Index publications and Wall Street's positive outlook.

The outlook remains positive with analyst consensus favoring Buy ratings (66.7%) and projecting 27.9% upside potential. Key opportunities include continued revenue growth and margin expansion, while risks involve organic search pressure in core products and macroeconomic sensitivity. The stock presents a compelling value proposition with attractive valuation multiples.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FLNA
47% Buy53% Sell
Avg holding period · 37 Days
NRDS
0% Buy100% Sell
Avg holding period · 45 Days

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA →

About Nerdwallet Inc

Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.

Read more on NRDS →